Roeleveld Peter P, de Klerk J C A
1 Department of Pediatric Intensive Care, Leiden University Medical center, Leiden, The Netherlands.
2 Department of Neonatal Intensive Care, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands.
World J Pediatr Congenit Heart Surg. 2018 Jan;9(1):10-21. doi: 10.1177/2150135117731725. Epub 2017 Nov 1.
Inotropes are frequently being used in children undergoing heart surgery to prevent or treat low cardiac output syndrome (LCOS). There is only limited evidence that inotropes actually positively influence postoperative outcome. Our aim was to describe the current international practice variation in the use of inotropes following congenital heart surgery.
We developed an online survey regarding the postoperative use of inotropes. We sent an invitation to all 197 registered members of the Pediatric Cardiac Intensive Care Society (PCICS) to participate in the survey. We also performed a systematic review of the literature.
Ninety-eight people (50%) responded, representing 62 international centers. Milrinone is routinely used perioperatively by 90 respondents (97%). Adrenaline/epinephrine is routinely used by 43%, dopamine by 36%, dobutamine by 11%, and levosimendan by 6%. Steroids are used routinely by 54% before initiating cardiopulmonary bypass. Vasopressin is used by 44% of respondents. The development of LCOS is monitored with lactate in 99% of respondents, physical examination (98%), intermittent mixed venous saturation (76%), continuous mixed venous saturation (13%), echocardiography (53%), core-peripheral temperature gap (29%), near-infrared spectrometry (25%), and 4% use cardiac output monitors (PiCCO, USCOM). To improve cardiac output, 42% add/increase milrinone, 37% add adrenaline, and 15% add dopamine. Rescue therapy is titrated individually, based on the patients' pathophysiology. A systematic review of the literature failed to show compelling evidence with regard to the benefit of inotropes.
Despite the lack of sufficient evidence, milrinone is used by the vast majority of caregivers following congenital heart surgery.
正性肌力药物常用于接受心脏手术的儿童,以预防或治疗低心排血量综合征(LCOS)。仅有有限的证据表明正性肌力药物确实能对术后结局产生积极影响。我们的目的是描述先天性心脏病手术后使用正性肌力药物的当前国际实践差异。
我们设计了一项关于术后使用正性肌力药物的在线调查。我们向小儿心脏重症监护学会(PCICS)的所有197名注册会员发出了参与调查的邀请。我们还对文献进行了系统综述。
98人(50%)做出回应,代表62个国际中心。90名受访者(97%)在围手术期常规使用米力农。43%的人常规使用肾上腺素,36%的人使用多巴胺,11%的人使用多巴酚丁胺,6%的人使用左西孟旦。54%的人在开始体外循环前常规使用类固醇。44%的受访者使用血管加压素。99%的受访者通过乳酸监测LCOS的发生,98%通过体格检查,76%通过间歇性混合静脉血氧饱和度,13%通过连续混合静脉血氧饱和度,53%通过超声心动图,29%通过核心-外周温度差,25%通过近红外光谱法,4%使用心输出量监测仪(脉搏指示连续心输出量监测仪、超声心输出量监测仪)。为提高心输出量,42%的人添加/增加米力农,37%的人添加肾上腺素,15%的人添加多巴胺。抢救治疗根据患者的病理生理情况进行个体化滴定。对文献的系统综述未能显示出关于正性肌力药物益处的令人信服的证据。
尽管缺乏充分证据,但绝大多数先天性心脏病手术后的护理人员仍使用米力农。